COVID-19

In response to the announcement that AstraZeneca is to move away from the non-profit model for COVID vaccines, Anna Marriott, Oxfam’s Health Policy Manager and spokesperson for the People’s Vaccine Alliance, said: “AstraZeneca is breaking its repeated and celebrated public promises of a non-profit vaccine for all countries for the duration of this pandemic and to never to make a profit in any low- and middle-income country from this publicly funded vaccine."
 

An international coalition of human rights law groups, public health experts, and civil society organisations is taking legal action against the US, UK, Germany, Norway, and Switzerland, on the grounds that these countries are in violation of international human rights law by failing to intervene on what has been an inequitable and racially discriminatory rollout of the vaccine and other COVID healthcare technologies. 

In response to the announcement that the World Health Organisation (WHO) has granted emergency use license for the COVID-19 vaccine, Covaxin, developed by Bharat Biotech in India, People’s Vaccine Alliance spokesperson and Oxfam Health Policy Manager, Anna Marriott, said: "Another approved vaccine to fight COVID-19 is fantastic news. We strongly encourage Bharat Biotech to show pandemic leadership and do the right thing for humanity by agreeing to share the vaccine technology and rights with the WHO's COVID Technology Access Pool, so that more manufacturers around the world can produce them.

At the end of the G20 Summit in Rome, Italy, Oxfam panned the lack of bold and effective action from the world leaders at such an important moment in the global response to the COVID-19 pandemic. 

Ahead of the G20 Summit in Rome, Italy, Oxfam calls on G20 leaders to take urgent action to dramatically scale up manufacturing and access to COVID-19 vaccines around the world, promote a fair economic recovery, fight hunger, lower dangerous greenhouse gas emissions, and help the poorest countries adapt to the climate change already happening.

In response to Merck’s announcement that it has granted a license for its promising COVID-19 pill to the Medicines Patent Pool, Robbie Silverman, Oxfam America’s Senior Manager for Private Sector Engagement, made the following statement:

“Merck’s move to license molnupiravir is welcome as it could indeed mean increased access to its promising COVID-19 drug in the poorest countries in the world.

Developing countries have been hit with an endless tide of inadequate gestures and broken promises from rich countries and pharmaceutical companies, who are failing to deliver billions of doses they promised while blocking the real solutions to vaccine inequality, according to a new report published today by the People’s Vaccine Alliance. 

The International Monetary and Financial Committee (IMFC) gave its approval today to set up a new IMF-administered Resilience and Sustainability Trust (RST) that will allow wealthy nations to channel some of their Special Drawing Rights (SDRs) to more vulnerable countries. In response, Nadia Daar, Head of Oxfam International’s Washington DC Office, said: “While it is positive that the RST will be accessible to a wide range of countries, including vulnerable middle-income countries hit hard by the COVID-19 pandemic, it is vital that the IMF deliver these funds on terms that are as close to grants as possible."

Overall, 155 million people around the world are living in crisis levels of food insecurity or worse. Around two out of every three of these people are going hungry primarily because their country is in war and conflict. Women and girls are disproportionally affected. They face extraordinary dangers to secure food, and yet, too often eating last and eating least. This is their story.

The Covid-19 pandemic has revealed and worsened the depth of inequality in West Africa. It has pushed millions into poverty. However, the pandemic offers West African governments a once-in-a-generation opportunity to invest heavily in inequality-busting policies by boosting public spending, making tax systems more progressive, and tackling joblessness and precarious work.